BIOZONE PHARMACEUTICALS, INC.
550 Sylvan Avenue, Suite 101
Engelwood Cliffs, NJ 07632
September 21, 2012
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Jeffrey P. Riedler
|Biozone Pharmaceuticals, Inc. (the “Company”)
Amendment No. 2 to Registration Statement on Form S-1
Filed July 2, 2012
File No. 333-176951
The Company hereby respectfully requests an extension to respond to the comment letter dated July 25, 2012 relating to the above-referenced filing and the Company intends to submit a response by September 28, 2012.
Very Truly Yours,
/s/ Elliot Maza
Chief Executive Officer and Chief Financial Officer